Find Clinical Trials | Cedars-Sinai

156 results found

Lung

Incorporating Pathologic Complete Response in Non-Small Cell Lung Cancer to Optimize Immunotherapy

The purpose of this study is to compare the usual approach of observation (closely watching a patient’s condition after surgery) to taking an immunotherapy drug, durvalumab (MEDI4736), in people with early-stage, non-small cell lung cancer ...

Kidney

Alliance, A032201, Ph3, Rand, RCC, Pembrolizumab vs Pembrolizumab + Tivozanib

Primary Objective: 1. To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone Secondary Objectives: 1. To compare overall survival ...

Prostate

Merck,MK-2400-001, Ph 3, open label, Prostate Ca, Ifinatamab Deruxtecan Versus Docetaxel

Primary Objective: To compare infinatamab deruxtecan (I-DXd) to docetaxel with respect to overall survival (OS) in participants with mCRPC. To compare I-DXd to docetaxel with respect to radiographic progression-free survival (rPFS) per Prostate Cancer Working ...

Anus, Breast, Lung, Other Female Genital, Ovary, Unknown Sites

Sumitomo Pharma America, Inc, SMP-3124-101, PhI/II, Open-label, SMP-3124LP, Solid tumors

Primary Objective: Dose Escalation: Determine the Recommended Phase 2 Dose (RP2D). Assess the safety and tolerability. Dose Expansion: Evaluate preliminary antitumor activity. Secondary Objectives: Dose Escalation: Establish the plasma PK profile of SMP-3124 and SMP-3124LP. Evaluate ...

Unknown Sites

SystImmune, Inc.BL-M07D1-ST-101, PhI, Open-label, Solid Tumors, BL-M07D1

Primary Objective: To assess the safety and tolerability of BL-M07D1 in metastatic or unresectable HER2-expressing tumors To determine the MTD if reached or MAD and two or more RDEs of BL-M07D1 Secondary Objectives: To characterize the ...